BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35862673)

  • 1. Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope.
    Ratcliff AN; Venner CM; Olabode AS; Knapp J; Pankrac J; Derecichei I; Gibson RM; Finzi A; Li Y; Mann JFS; Arts EJ
    J Virol; 2022 Jul; 96(14):e0185121. PubMed ID: 35862673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
    Gardner MR; Fellinger CH; Prasad NR; Zhou AS; Kondur HR; Joshi VR; Quinlan BD; Farzan M
    J Virol; 2016 Sep; 90(17):7822-32. PubMed ID: 27334589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
    Anang S; Richard J; Bourassa C; Goyette G; Chiu TJ; Chen HC; Smith AB; Madani N; Finzi A; Sodroski J
    J Virol; 2022 Sep; 96(17):e0063622. PubMed ID: 35980207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
    Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
    J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.
    Grupping K; Selhorst P; Michiels J; Vereecken K; Heyndrickx L; Kessler P; Vanham G; Martin L; Ariƫn KK
    Retrovirology; 2012 May; 9():36. PubMed ID: 22551420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
    Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
    J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
    Tolbert WD; Nguyen DN; Tehrani ZR; Sajadi MM; Pazgier M
    mBio; 2021 Aug; 12(4):e0127421. PubMed ID: 34281393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.
    Zou S; Zhang S; Gaffney A; Ding H; Lu M; Grover JR; Farrell M; Nguyen HT; Zhao C; Anang S; Zhao M; Mohammadi M; Blanchard SC; Abrams C; Madani N; Mothes W; Kappes JC; Smith AB; Sodroski J
    J Virol; 2020 May; 94(10):. PubMed ID: 32161177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies.
    Yoshimura K; Harada S; Boonchawalit S; Kawanami Y; Matsushita S
    J Gen Virol; 2014 Aug; 95(Pt 8):1816-1826. PubMed ID: 24795449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
    Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
    J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
    Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
    J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
    Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
    Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers.
    Yang Z; Dam KA; Gershoni JM; Zolla-Pazner S; Bjorkman PJ
    J Virol; 2022 Dec; 96(24):e0108222. PubMed ID: 36448805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic Correlates of HIV-1 Macrophage Tropism.
    Arrildt KT; LaBranche CC; Joseph SB; Dukhovlinova EN; Graham WD; Ping LH; Schnell G; Sturdevant CB; Kincer LP; Mallewa M; Heyderman RS; Rie AV; Cohen MS; Spudich S; Price RW; Montefiori DC; Swanstrom R
    J Virol; 2015 Nov; 89(22):11294-311. PubMed ID: 26339058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.
    Alsahafi N; Debbeche O; Sodroski J; Finzi A
    PLoS One; 2015; 10(4):e0122111. PubMed ID: 25849367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.